Company news

Alligator Bioscience AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alligator Bioscience to present at BioStock's "Investing in Life Science" event

September 5, 2025

Alligator Announces Evaluation and Option Agreement Covering RUBY(TM) Antibody Format

September 2, 2025

Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB

August 27, 2025

Alligator Bioscience Provides Highlights from R&D Event 2025

August 20, 2025

Alligator Bioscience to Host Virtual R&D Day on 19 August 2025

August 14, 2025

Alligator Bioscience Announces Upcoming Presentation of REACtiVe-2 Phase 1 Data at ESMO Congress 2025

July 25, 2025

Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer

July 14, 2025

Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update

July 10, 2025

Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025

July 1, 2025

Alligator Receives Positive Scientific Advice from EMA on Phase 3 Trial of Mitazalimab

June 17, 2025

Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer

June 13, 2025

Biomarker Data from Alligator Bioscience’s OPTIMIZE-1 Trial Presented at ASCO 2025 Annual Meeting

June 3, 2025

Alligator Bioscience AB Carries Out Directed Issues to Guarantors in Connection with Exercise of Warrants Series TO 12

May 26, 2025

Alligator Bioscience Announces European Orphan Drug Designation for HLX22 in Gastric Cancer

May 26, 2025

Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data at ASCO 2025 Annual Meeting

May 23, 2025

Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 12

May 21, 2025

Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency

May 20, 2025

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12

May 20, 2025

Alligator Bioscience to Attend ASCO 2025 Annual Meeting

May 12, 2025

Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

May 9, 2025

Alligator Bioscience Completes Phase 3 GMP Manufacturing of Mitazalimab, Remains on Track for Trial Initiation with Partner

May 9, 2025

Alligator Bioscience Updates Dividend Policy

May 8, 2025

Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025

May 7, 2025

Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

April 28, 2025

Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update

April 24, 2025

Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.

April 23, 2025

← Newer news releases

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.